Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

3 of 0 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03846193Phase 1Terminated

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Role: lead

NCT04566445Phase 2Terminated

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Role: lead

NCT04437368Phase 2Terminated

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Role: lead

NCT03894020Terminated

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Role: lead

NCT05481827Phase 2Enrolling By Invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Role: lead

All 5 trials loaded